Axim Biotechnologies Inc (AXIM)

AXIM Biotechnologies, Inc. is a healthcare company focused on diagnostic solutions for eye-related conditions. Its portfolio includes point-of-care tests designed to help eye-care physicians identify and measure biomarkers linked to aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including an ocular total immunoglobulin E allergy test and a lactoferrin ADDE test. The company also runs a full-service center that supports custom biomarker and biopharmaceutical research, assay development, clinical sample testing, and precision data delivery. In addition, AXIM is developing diagnostic products for early cancer detection, treatment response monitoring, and recurrence tracking, along with rapid tests related to COVID-19. Incorporated in 2010 and based in San Diego, California, the company was previously known as Axim International Inc. before changing its name in 2014.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.